FDA Agrees to Phase 1 Trial of ET3, Gene Therapy for Hemophilia A

FDA Agrees to Phase 1 Trial of ET3, Gene Therapy for Hemophilia A

Hemophilia News Today

Image

Please enable the javascript to submit this form

Supported by educational grants from Bayer, BioMarin, CSL Behring, Freeline Therapeutics Limited, Pfizer Inc., Spark Therapeutics, and uniQure, Inc.

Essential SSL